{
    "nctId": "NCT00237211",
    "briefTitle": "Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer",
    "officialTitle": "Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Postmenopausal Women With Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Safety during treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically documented breast cancer.\n* Patients with hormone receptor (ER and/or PgR) status of positive or unknown\n* Patients who have been amenorrheic for the preceding 12 months or more.\n* Patients who are 20 years or older and younger than 75 years.\n* Patients with a history of postoperative adjuvant therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. The endocrine therapy, however, should not exceed one regimen.\n* Patients with progressing lesions.\n* Patients with sufficient organ function to evaluate the safety\n* Patients whose performance status (PS) is classified in 0\uff5e2.\n* Patients who have no residual effects from previous treatments\n\nExclusion Criteria:\n\n* Patients with other concurrent or previous malignant disease (excluding uterine carcinoma in-situ).\n* Patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease)\n* Patients who have previously received aromatase inhibitor.\n* Patients who have lymphangitis-type lung metastasis or symptomatic brain metastasis.\n\nOther protocol-defined inclusion / exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}